Compound Evidence File
#EC-2026-0583
Tamoxifen (Nolvadex)
Filed under Oral Tablets. The bureau holds 131 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Mar 2026 | 28 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 18 Feb 2026 | 12 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jan 2026 | 15 Mar 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Dec 2025 | 17 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Apr 2026 | 5 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Mar 2026 | 18 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 15 May 2026 | 2 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Apr 2026 | 22 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 7 May 2026 | 26 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Jun 2026 | 16 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 14 Apr 2026 | 5 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Nov 2025 | 5 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Dec 2025 | 20 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Apr 2026 | 16 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 20 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 4 May 2026 | 24 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 9 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 9.9 | 15 Mar 2026 | 8 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 24 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 4 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Apr 2026 | 12 Jul 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 9.5 | 9.5 | 9.5 | 14 Jan 2025 | 14 Jan 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 9.2 | 9.2 | 9.2 | 2 Jul 2025 | 2 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 9.1 | 7.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 9.0 | 9.0 | 9.0 | 3 Jul 2025 | 3 Jul 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.9 | 8.3 | 9.5 | 24 May 2026 | 24 May 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 8.9 | 8.9 | 8.9 | 24 Apr 2025 | 24 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.6 | 8.3 | 8.8 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.3 | 6.9 | 9.5 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.1 | 8.0 | 8.2 | 21 May 2026 | 21 May 2026 |
| UtherCASE #VI-2026-0902 | X | 4 | 7.6 | 6.3 | 8.7 | 6 May 2025 | 21 May 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 2 | 7.4 | 6.6 | 8.2 | 13 Feb 2025 | 24 May 2026 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 7.4 | 7.4 | 7.4 | 13 Feb 2025 | 13 Feb 2025 |
| OupeptideCASE #VI-2026-0435 | X | 1 | 7.4 | 7.4 | 7.4 | 21 May 2025 | 21 May 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 2 | 7.2 | 6.0 | 8.3 | 21 May 2025 | 24 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 7.1 | 7.1 | 7.1 | 2 Apr 2025 | 2 Apr 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 6.3 | 5.8 | 6.8 | 28 Mar 2025 | 24 May 2026 |
| YimeiCASE #VI-2026-0081 | X | 5 | 5.8 | 4.6 | 8.2 | 7 May 2025 | 23 May 2026 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 5.8 | 5.8 | 5.8 | 2 Jul 2025 | 2 Jul 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 4.8 | 4.8 | 4.8 | 11 Jun 2025 | 11 Jun 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 4.7 | 4.7 | 4.7 | 11 Jun 2025 | 11 Jun 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 2 | 3.9 | 2.3 | 5.6 | 7 May 2025 | 23 May 2026 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.5 | 0.5 | 0.5 | 2 Jul 2025 | 2 Jul 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
Open any subject to view the batch-level evidence for Tamoxifen (Nolvadex) alone.